摘要
目的分析基于新的分类算法研究抗乙肝病毒药的相互作用。方法选择患有慢性乙肝疾病的患者86例,根据患者的病情需要以及尊重患者自我意愿的前提下,把患者分为两组各43例,其中一组使用拉米夫定联合中药治疗进行抗病毒治疗,而另外一组使用干扰素联合抗病毒治疗,同时对两组患者均使用基于概率向量分类机(PCVM),并有效结合DX打分特征选择方法,对数据进行评估预测。结果抗病毒的协同作用表现为阳性的病例,拉米夫定组的患者有37例,干扰素组的患者有39例,同时两组患者的药物浓度均没有出现下降,说明治疗乙肝的抗病毒药物和中药治疗乙肝的药物具有潜在的临床显著药物相互作用。结论新的分类算法可以在有限的临床数据基础上提供更加准确的数据结果,具有一定的临床实用价值。
Objective Analysis of the interaction of Anti-HBV drugs based on a New Classification algorithm.Methods From May 2016 to December 2017,86 patients with chronic hepatitis B were selected from May 2016 to December 2017 in our hospital.According to the needs of the patients and the premise of respecting the self-wishes of the patients,the patients were divided into two groups:43 cases each.One group of patients was treated with lamivudine combined with traditional Chinese medicine for antiviral therapy,while the other group was treated with interferon combined with antiviral therapy.At the same time,the patients in both groups were compared and evaluated the drug interaction performance by using the probability vector classifier(PCVM)and the DX scoring feature selection method.Results According to the data analysis,there were 37 cases in lamivudine group and 39 cases in interferon group in which the synergistic effect of anti-virus was positive,and there was no decrease in drug concentration in both groups.It shows that antiviral drugs for hepatitis B and traditional Chinese medicine for treating hepatitis B have potential clinical significant drug interactions.Conclusion The new classification algorithm can provide more accurate data results on the basis of limited clinical data,and has certain clinical practical value.
作者
王华富
桂志红
刘丽仙
丁汀
商振球
Wang Huafu;Gui Zhihong;Liu Lixian;Ding Ting S;hang Zhenqiu(Lishui City People's Hospital,Lishui 323000,China)
出处
《哈尔滨医药》
2020年第1期67-69,共3页
Harbin Medical Journal
基金
2016年浙江省药学会医院药学科研专项(2016ZYY40)。
关键词
新分类算法
研究
抗乙肝病毒药
慢性
中药
相互作用
New classification algorithm
Study
Anti-hepatitis B virus drug
Slow in taking effect
Traditional Chinese medicine
Interact
